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ABSTRACT
Several lymphangiogenic factors, such as vascular endothelial growth factors 
(VEGFs), have been found to drive the development of lymphatic metastasis in bladder 
cancer (BCa).
Here, we have analyzed the gene expression of lymphangiogenic factors in tissue 
specimens from 12 non-muscle invasive bladder cancers (NMIBC) and 11 muscle 
invasive bladder cancers (MIBC), considering tumor and tumor-adjacent normal 
bladder areas obtained from the same organs. We then compared the results observed 
in patients with those obtained after treating human primary bladder microvascular 
endothelial cells (MEC) with either direct stimulation with VEGF-A or VEGF-C or by 
co-culturing (trans-well assay) MEC with bladder cancer cell lines varying in VEGF-A 
and VEGF-C production based on tumor grade.
The genes of three markers of lymphatic endothelial commitment and 
development (PDPN, LYVE-1 and SLP-76) were significantly overexpressed in tissues 
of MIBC patients showing positive lymphovascular invasion (LVI+), lymph node 
metastasis (Ln+) and tumor progression. Their expression was also significantly 
enhanced either after direct stimulation of MEC by VEGF-A and VEGF-C or in the 
trans-well assay with each bladder cancer cell line.
SLP-76 showed the highest gene expression. Both VEGF-A and VEGF-C also 
enhanced the expression of SLP-76 protein in MEC. However, a correlation between 
increase of SLP-76 gene expression and the ability of MEC to migrate could only be 
seen after induction by VEGF-C.
The significant expression of SLP-76 in LVI+/Ln+ progressive MIBC and its 
overexpression in MEC after VEGF-A and VEGF-C stimulation suggest the need to 
develop this regulator of developmental lymphangiogenesis as a diagnostic tool in 
BCa.
INTRODUCTION
Bladder cancer (BCa) is the most frequent cancer 
in the urogenital tract in both sexes, with an estimated 
77,000 new cancer cases and approximately 16,000 cancer 
deaths in the United States in 2016 [1, 2]. BCa is generally 
either classified as non-muscle invasive (NMIBC; ~80%), 
hereafter referred to as superficial, or as muscle-invasive 
cancer (MIBC), based on the natural history of the 
tumors. Among the superficial tumors, 50%–70% recur 
after transurethral resection (high-risk NMIBC) [3] and 
10%–20% thereof show progression to MIBC [4]. Due to 
the worse prognosis of MIBC, there is great interest in 
identifying markers that can diagnose superficial cancers 
with an increased risk of progression [5, 6]. Approximately 
25% of patients undergoing radical cystectomy for MIBC 
show lymph node metastases (Ln+) [7] and Ln+ are one 
of the most important predictors of cancer patient outcome 
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[8, 9]. Therefore, there is great interest in studying the role 
of lymphangiogenic growth factors in patients bearing BCa 
with an increased risk of disease progression (Ln+) [10]. 
Vascular endothelial growth factors (VEGFs), in particular 
VEGF-C and VEGF-D, have been described as regulators 
of lymphangiogenesis in BCa [11] and the expression of 
VEGF-C was found to correlate with pelvic lymph node 
metastases and poor prognosis in this malignancy [12]. 
In our setting, high VEGF-D serum levels were shown to 
predict lymph node metastasis in patients with invasive 
BCa [13]. VEGFs have been proposed to determine a 
state of cancer invasion and dissemination by increasing 
the expression of factors involved in lymphatic vessel 
development and maturation [14]. The lymphatic vessel 
density (LVD) was found to strongly correlate with lymph 
node metastases in patients with invasive BCa [15].
Despite above investigations, the synergic role of 
VEGFs in eliciting a peculiar lymphoangiogenic profile 
in BCa with a high risk of lymphatic tumor spreading has 
not been entertained yet. It is thus of utmost importance to 
identify lymphangiogenic markers in node-positive BCa 
for diagnostic purposes and to redirect treatment options 
[16] from targeting the VEGF/VEGFR pathways [17].
RESULTS
Gene expression analysis of lymphangiogenic 
factors in tumor specimens of LVI+/Ln+ MIBC 
patients
The gene expression of factors involved in tumor 
lymphangiogenesis was evaluated in tumor tissues of 
23 BCa patients and in as many tumor-adjacent normal 
bladder tissues. The following genes were tested: VEGF-A, 
C, and D and their tyrosine kinase receptors (VEGFR-2 
and VEGFR-3); podoplanin (PDPN) as a specific 
lymphatic vessel marker; lymphatic vessel endothelial 
receptor 1 (LYVE-1) as marker for lymphovascular 
invasion; the C-C chemokine receptor type 7 (CCR7) as 
a chemoattractant for endothelial cells; angiopoietin-2 
(Ang-2) as a modulator of proliferation and migration 
of endothelial cells and SLP-76 for microenvironmental 
involvement in lymphangiogenesis [18–20]. Among the 
23 patients analyzed in this study, 11 (48%) were <70 yrs 
and 12 (52%) were ≥70 yrs; 16 (70%) were male and 7 
(30%) female. Out of the 23 patients, 12 (52%) and 11 
(48%) were diagnosed with non-muscle invasive bladder 
cancer (NMIBC) and muscle invasive bladder cancer 
(MIBC), respectively (see Material and Methods). All 23 
BCa were shown to be of high histologic grade. Eight out 
of 23 patients (35%) had lymphovascular invasion (LVI+) 
and 6 out of 23 (26%) were diagnosed as lymph node 
positive (Ln+). Seven out of 23 patients (30%) showed 
tumor progression (Table 1). A significant association 
between lymphovascular invasion (LVI+) and lymph node 
metastasis (Ln+) was observed (p < 0.001). Both LVI+ and 
Ln+ associated with age at diagnosis (p < 0.01). Six out 
of the 7 patients with tumor progression were LVI+/Ln+ 
(LVI+, p < 0.01 and Ln+, p < 0.001) (Table 1).
The expression of all factors in tumor tissues was 
not significantly different from that in paired tumor-
adjacent normal tissues, except for VEGF-A (p < 0.05) 
(Figure 1A) and not significantly related to the patient’s 
clinical information. In contrast, the fold change in gene 
expression of lymphangiogenic factors observed in tumor 
tissues, relative to those in tumor-adjacent normal tissues 
as reference genes, showed a clear contribution of the 
tumor-induced lymphatic vasculature to BCa progression. 
Indeed, the expression of three factors mainly involved 
in lymphatic commitment and development, PDPN (p 
< 0.05), LYVE-1 (p < 0.05) and SLP-76 (p < 0.05), 
was significantly higher in patients with at least one 
clinicopathological parameter (w+; n = 12), compared 
with patients without these properties (w/o; n = 11; LVI-/
Ln- NMIBC) (Figure 1B, Table 2). Even more robust was 
the significant overexpression of PDPN, LYVE-1 and 
SLP-76 (p < 0.01) when gene expression fold changes 
in the 6 LVI+/Ln+ MIBC patients (Pt 6, 7, 10, 12, 18, 
20) showing tumor progression and in the 11 LVI-/Ln- 
NMIBC patients (Pt 1, 3, 4, 5, 9, 11, 16, 17, 21, 22, 23) 
without progression were compared (Figure 1C, Table 2).
In vitro crosstalk between MEC and BCa cells 
confirmed the gene expression profile observed 
ex vivo in patients
To mimic the in vivo cross talk between BCa and 
endothelial cells and to reconfirm the observations made 
ex vivo in patients, we decided to prime MEC with tumor 
derived soluble factors released by three human BCa 
cell lines (RT4, HTB-9 and T24) with different tumor 
grading using a trans-well co-culture assay. The human 
uroepithelial cell line UROtsa was used as control. 
Gene expression analysis of lymphatic vessel markers 
and vessel-forming factors, such as lymphatic vessel 
endothelial receptor 1 (LYVE-1), angiopoietin-2 (Ang2), 
podoplanin (PDPN), chemokine ligand 21 (CCL21), 
prospero-related homeobox 1 (PROX-1), forkhead box 2 
(Fox-2), ephrin-B2 (EFNB-2), vascular endothelial growth 
factor receptor 2 (VEGFR-2) and 3 (VEGFR-3) [18–20], 
and CD31 [21] was carried out. Due to the relevant 
overexpression in patients, SLP-76 was also tested. A 
constitutive gene expression analysis was performed to 
compute fold changes. Hence, MEC were cultured without 
stimuli for 48 h. Eight of the tested factors showed and 
maintained high gene transcription over time compared 
with CD31, while two (CCL21 and SLP-76) were weakly 
expressed (Supplementary Figure 1).
The three MEC/RT4, MEC/HTB-9, and MEC/T24 
co-cultures showed a similar gene expression profile of 
the factors and receptors studied. Particularly, PDPN 
gene expression levels were significantly increased 
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above the 2-fold threshold in these three co-cultures 
compared with MEC/UROtsa: (MEC/RT4 2.2-fold ± 
0.5; MEC/HTB-9 3.2-fold ± 0.1; MEC/T24 2.6-fold ± 
0.6; MEC/UROtsa 1.4-fold ± 0.2; p < 0.05), while SLP-
76 gene levels were expressed at significantly higher 
levels over the 2-fold baseline (MEC/RT4 14-fold ± 
2.4; MEC/HTB-9 32.2-fold ± 6.8; MEC/T24 17.7-fold ± 
0.8; MEC/UROtsa 3.1-fold ± 0.3; p < 0.01). In contrast, 
LYVE-1 maintained non-significant gene expression 
slightly below the 2-fold baseline for all co-cultures 
compared with MEC/UROtsa (MEC/RT4 1.6-fold ± 0.5; 
MEC/HTB-9 1.7-fold ± 0.7; MEC/T24 1.96-fold ± 0.5; 
MEC/UROtsa 1.3-fold ± 0.2; Figure 2A).
The effect of a direct VEGF-A and VEGF-C 
induction of MEC at concentrations similar to 
that produced by BCa cell lines
To attribute the genetic profile observed after 
culturing MEC with BCa cell lines to VEGF activity, 
we performed a direct stimulation of MEC with both 
VEGF-A and VEGF-C. Concentrations were established 
Table 1: Distribution of clinicopathologic characteristics of patients (n = 23) who underwent radical cystectomy for 
BCa and their association with lymphovascular invasion (LVI) and lymph node staging (Ln)
Variable Categorization n analyzable % 
 associationc  
 LVI+  Ln+
Age at diagnosis        
 <70 years 11 48 7  6  
 ≥70 years 12 52 1 <0.01 0 <0.01
Sex        
 male 16 70 5  3  
 female 7 30 3 0.7 3 0.3
Tumor stagea        
 NMIBC 12 52 2  1  
 MIBC 11 48 6 0.09 5 0.07
Histologic gradeb        
 low grade 0 0 0  0  
 high grade 23 100 8 1 6 1
Lymphovascular invasion 
(LVI)
       
 positive 8 35 -  6  
 no LVI 15 65 - n.a. 0 <0.001
Lymph node staging (Ln)        
 positive 6 26 6  -  
 negative 17 74 2 <0.001 - n.a.
Tumor progression        
 yes 7 30 6  6  
 no 16 70 2 <0.01 0 <0.001
Cancer death        
 yes 1 4 1  1  
 no 22 96 7 0.3 5 0.3
a Stage grouping according to the European Association of Urology 2016 guidelines [3]
b Grading according to the 2004 WHO classification system
c Fisher's exact test, 2-sided
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Figure 1: Gene expression analysis of BCa tumor tissues as compared with normal bladder tissues. A. Gene expression of 
10 factors involved in tumor lymphangiogenesis in BCa tissues (T) and in normal bladder tissues obtained from the same patients (N). No 
significant differences were found, except for the higher expression of VEGF-A in tumor tissues than in normal tissues (Wilcoxon matched-
paired test, p < 0.05). The 2–ΔΔCt method was used to compute the gene expression fold change in all factors, setting β-actin gene expression 
equal to 1. All values ≤10−7 were considered undetectable. B. Gene expression of the same 10 factors in patients stratified according to 
clinicopathologic characteristics (white boxes: at least one or w+; n = 12: gray boxes: without or w/o; n = 11). Three genes were expressed 
at significantly higher levels in w+ patients than in w/o patients: PDPN p < 0.05; LYVE-1 p < 0.05; SLP-76 p < 0.05 (Mann Whitney U test). 
For VEGF-D (*) medians are not significantly different. C. PDPN, LYVE-1, and SLP-76 were overexpressed in LVI+/Ln+ MIBC patients 
(n = 6) showing tumor progression (scattered dot plot) as compared with those NMIBC patients with no progression (n = 12; gray boxes) 
(Mann Whitney U test; p < 0.01). For each test performed, a 2–ΔΔCt method was used to compute gene expression fold change in all factors 
in tumor tissues relative to their gene expression in paired normal tissues. Beta-actin was used as the reference gene. All values ≤10−7 were 
considered undetectable.
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by computing fold changes in gene expression and protein 
release at a constitutive level over 72 h of each tumor cell 
line used in this study based on their tumor grade. UROtsa 
cells were used as a control (supplementary material). 
We noted that VEGF-C was produced at a significantly 
higher level than VEGF-A by the two high-grade BCa 
cell lines HTB-9 and T24 (p < 0.0001 and p < 0.001, 
respectively), whereas only the low-grade cell line RT4 
produced significant amounts of VEGF-A (p < 0.01). The 
expression of VEGF-D was negligible and non-significant 
in all cell lines tested (Supplementary Figure 2A and 
2B). In keeping with gene expression data, the RT4 cells 
produced the highest amount of VEGF-A protein among 
the three cancer cell lines tested (p < 0.01) and compared 
with the UROtsa cell line (p < 0.05). In contrast, there was 
a significant release of VEGF-C protein by all cell lines, 
although to different extents (p < 0.05; Supplementary 
Figure 2C).
Table 2: Distribution of clinicopathological parameters among patients
Patients Tumor stage
Lympho-
vascular 
invasion
Positive 
lymph node Progression Cancer death Parameters
n = 23 MIBC= 1, NMIBC = 0 yes = 1, no = 0 yes = 1, no = 0 yes = 1, no = 0 yes = 1, no = 0 yes = 1, no = 0
Pt 1 0 0 0 0 0 0
Pt 2 1 0 0 1 0 1 (2)
Pt 3 0 0 0 0 0 0
Pt 4 0 0 0 0 0 0
Pt 5 0 0 0 0 0 0
Pt 6 1 1 1 1 0 1 (4)
Pt 7 1 1 1 1 0 1 (4)
Pt 8 1 0 0 0 0 1 (1)
Pt 9 0 0 0 0 0 0
Pt 10 1 1 1 1 1 1 (5)
Pt 11 0 0 0 0 0 0
Pt 12 1 1 1 1 0 1 (4)
Pt 13 1 0 0 0 0 1 (1)
Pt 14 1 1 0 0 0 1 (2)
Pt 15 1 0 0 0 0 1 (1)
Pt 16 0 0 0 0 0 0
Pt 17 0 0 0 0 0 0
Pt 18 1 1 1 1 0 1 (4)
Pt 19 0 1 0 0 0 1 (1)
Pt 20 1 1 1 1 0 1 (4)
Pt 21 0 0 0 0 0 0
Pt 22 0 0 0 0 0 0
Pt 23 0 0 0 0 0 0
with (w+) 11 8 6 7 1 12
without (w/o) 12 15 17 16 22 11
In bold: LVI+/Ln+ MIBC patients with progression (n = 6)
In italics: LVI-/Ln- NMIBC patients without progression (n = 11)
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Figure 2: Gene expression profile of lymphatic vessel-forming factors and VEGFRs by cell line trans-well assay. A. 
MEC at 80% confluence were co-cultured for 24 h with either BCa cell line (test) or UROtsa cells (control) previously grown in co-culture 
inserts. A significant overexpression of two genes (PDPN and SLP-76) over the 2-fold baseline (arbitrary cut-off) was observed in all three 
BCa cell lines, as compared with control (UROtsa; * p < 0.05 and ** p < 0.01, respectively). B. The cells showed different factor and 
receptor profiles upon VEGF-A and VEGF-C stimulation at the standard concentration of 50 ng/ml with a stronger Fox-2 and EFNB-2 
increase (20-fold) after VEGF-C stimulation, as compared to that after VEGF-A stimulation (p < 0.001, Mann Whitney U test). C. Although 
to a lesser extent (approximately 10-fold less), the factor and receptor profile upon VEGF-A and VEGF-C stimulation at concentrations of 
17 ng/ml and 2 ng/ml, respectively (“established” concentration; see Table 2 for calculation) was similar to the pattern induced at standard 
concentrations. For both tests (standard and established concentrations), the 2–ΔΔCt method was used. Fold increase was calculated as the 
gene expression fold change in all factors and receptors above their constitutive expression (2-fold baseline as cut-off). CD31 was used as 
the reference gene. Error bars represent the mean ± SD of three replicates.
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The stimulation of MEC with either standard (50 
ng/ml) or established concentrations of VEGF-A (17 
ng/ml) and VEGF-C (2 ng/ml; supplementary material; 
Table 3) generated a gene profile similar to the one 
observed after performing the trans-well assay, except 
for the overexpression of Fox-2 and EFNB-2 upon 
direct stimulation with VEGF-C. The increase in gene 
transcript of PDPN, LYVE-1, and SLP-76 over the 2-fold 
baseline was observed upon either VEGF-A or VEGF-C 
stimulation at either standard (Figure 2B) or established 
concentrations (Figure 2C).
The effect of VEGF-C stimulation on SLP-76 
expression in MEC
Among the genes overexpressed after MEC 
induction, SLP-76 showed the highest expression. 
Notably, direct MEC stimulation with VEGF-A and 
VEGF-C at either standard (VEGF-A–50 ng/ml 50.54-
fold ± 9.1; VEGF-C–50 ng/ml 393.8-fold ± 109) or 
established concentrations (VEGF-A–15 mg/ml 5.29-
fold ± 0.5; VEGF-C–2 ng/ml 12.16-fold ± 2.7) induced 
a fold change in SLP-76 gene expression similar to that 
elicited by co-culturing MEC with either BCa cell line. 
Overall, VEGF-C at the standard concentration of 50 
ng/ml elicited the highest SLP-76 amount, similarly to 
that induced by anti-CD3 treated CD8 T cells (p = 0.06) 
(Figure 3A).
The SLP-76 gene overexpression observed by co-
culturing MEC with BCa cells encouraged us to also 
investigate SLP-76 protein secretion in these cells under 
VEGF induction. The analysis was carried out by using 
50 ng/ml of VEGF-A and VEGF-C, as no relevant protein 
expression of SLP-76 was detectable after stimulation 
with established concentrations of growth factors 
compared with SLP-76 expression in anti-CD3 induced 
human CD8 T cells (Figure 3B). Due to the specific 
cell source used (MEC) in this study, we also tested 
human dermal lymphatic endothelial cells from juvenile 
foreskin (HDLEC, hereafter LEC), which are reported 
not to express SLP-76. As expected, we noted that the 
constitutive gene expression of SLP-76 in LEC was 
completely absent and that the induced gene expression 
upon stimulation (either direct or by trans-well assay) 
was negligible (Ct values below the reliable limit of 
detection; data not shown). SLP-76 protein production 
was then analyzed in both MEC and LEC after 3, 6 and 
12 h of VEGF stimulation by both western blot and 
immunofluorescence (IF) assays. In western blot analysis, 
we observed an increase in SLP-76 protein production 
in MEC 3 h after VEGF-A and VEFG-C stimulation, 
compared with the basal expression of SLP-76 in non-
stimulated MEC (Figure 3C). The amount of SLP-76 was 
maintained 6 h after stimulation with VEGF-C but was 
drastically reduced 6 h after stimulation with VEGF-A 
(Figure 3C). The SLP-76 protein production and rate of 
concentration after VEGF stimulation, as detected by 
western blot assay, was confirmed by IF assay. Notably, a 
longer induction with VEGF-C correlated with a change 
in MEC morphology (Figure 3D). In addition, when 
performing a migration assay (wound healing assay) 
of MEC stimulated over 24 h with either VEGF-A or 
Table 3: Established concentrations for VEGF-A and VEGF-C
Amount of VEGFs: pg/cell per size of growth area   
      mean
Factor Cell line 150 cm2 75 cm2 25 cm2 9.6 cm2 pg/cell*
VEGF-A RT4 2,02-1 1.49-1 1.31-1 1,07-1 1.47-1
VEGF-C RT4 7.32-3 8,01-3 8,11-3 1,05-2 8.50-3
VEGF-C HTB-9 1,09-2 1.42-2 1.25-2 2.39-2 1.54-2
VEGF-C T24 2,03-2 1.82-2 1.38-2 1.96-2 1.80-2
*Normalized amount      
Calculation of established concentrations (ng)    
Factor Cell line n of cells* pg/cell total concentration in ng
VEGF-A RT4 117206 1.47-1 1.734 17 ng  
VEGF-C RT4 117206 8.50-3 9.962 1 ng  
VEGF-C HTB-9 132685 1.54-2 2,043 2 ng  
VEGF-C T24 163042 1.80-2 2.933 3 ng  
average   1.39-2 1.993 2 ng  
*insert size= 4.2 cm2      
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Figure 3: SLP-76 expression and production in MEC. A. The SLP-76 gene expression upon VEGF stimulation (at either 
concentration) and under bladder cell line trans-well assay was compared with SLP-76 gene expression elicited in anti-CD3 treated 
CD8 T cells (positive control). SLP-76-fold increase after direct MEC stimulation or priming with cell lines was calculated as gene 
expression 2-fold over its constitutive expression (arbitrary cut-off). SLP-76-fold increase in anti CD3 treated CD8 T cells was calculated 
as gene expression 2-fold over SLP-76 gene expression in non-stimulated CD8. Error bars represent the mean ± SD of three replicates. 
B. Representative fluorescent-activated cell sorting (FACS) dot plot analysis of in vitro SLP-76 intracellular staining in anti-CD3 treated 
CD8 T cells (upper right panel) and VEGF-C (2 ng/ml medium right panel) or VEGF-A (17 ng/ml lower right panel) stimulated CD31+ 
MEC, as compared with isotype staining (all left panels). Overlaid histograms refer to mean fluorescent intensity (MFI) of in vitro SLP-76 
intracellular staining of CD8 T cells upon anti-CD3 induction (above) or MEC after VEGF-C (middle) or VEGF–A (below) stimulation 
compared with isotype staining. C. Western blot showing SLP-76 expression in MEC stimulated with either VEGF-A or VEGF-C at 
50 ng/ml, over 3 and 6 h, as compared with SLP-76 expression in human CD8 T cells treated with anti-CD3 mAb (CD8 vs αCD3). D. 
A representative image by fluorescence microscopy (scale bar 400 μm) of MEC after 3 and 6 h of stimulation with either VEGF-A or 
VEGF-C (50 ng/ml). The SLP-76 basal staining (no stimulation) for both cell lines (MEC right and LEC left) is also reported. MEC were 
immunostained for SLP-76 (Cy-3; red), cytoskeleton (phalloidin; green), and nucleus (DAPI; blue). E. MEC migration was assessed by 
a scratch wound healing assay, as shown in one representative picture (scale bar 50 μm) by confocal microscopy after 24 h of VEGF-C 
stimulation at the standard concentration. Cells were cultured in 6-well plates and allowed to reach 80% confluence before scratching 
vertically and horizontally (see symbol bottom right in the upper panel). Histograms represent migration potential of cells based on the 
quantification of empty area (% closure rate) as compared with time 0 (100% empty area) for VEGF-A (gray bar) or VEGF-C (black bar) 
(p < 0.05; Mann Whitney U test). Error bars represent the mean ± SD of three replicates. F. MEC closure rates were plotted against gene 
expression of PDPN, LYVE-1, and SLP-76 after VEGF stimulation. The 3 time points tested (0, 16, and 24 h) were reported. SLP-76 upon 
VEGF-C stimulation (black circle) showed a significant linear correlation between the increase in gene expression and the percentage 
closure rate of MEC (r = 0.99, p < 0.05; Pearson correlation coefficient), as compared with VEGF-A stimulation (open circle) and with both 
other factors upon both stimulations (PDPN; black and open square) and LYVE-1; black and open triangle).
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VEGF-C at a concentration of 50 ng/ml, a higher migration 
capacity of MEC (higher closure rate) was particularly 
observed after stimulation with VEGF-C (p < 0.05; Figure 
3E). Finally, when plotting MEC migration activity against 
VEGF-specific gene upregulation of PDPN, LYVE-1, and 
SLP-76, we observed a significant correlation between 
increment of gene molecules and an increase in closure 
rates only for SLP-76 after stimulation with VEGF-C 
(p < 0.01; Figure 3F). In keeping with gene expression 
analysis, we could not find SLP-76 expression in LEC, 
either constitutively or upon induction, as documented by 
IF in LEC showing basal SLP-76 expression (Figure 3D).
DISCUSSION
As a solid malignancy, BCa depends on 
lymphangiogenesis for tumor invasion and dissemination 
[22]. It has been seen that the expression of VEGFs 
and their receptor VEGFR-2 was significantly higher in 
invasive than in non-invasive BCa, and that this finding 
is associated with disease recurrence [23]. In addition, the 
same study also showed significantly higher expression 
of VEGFs in tumor tissue than in the adjacent normal 
bladder mucosa [23]. The gene profile analysis of 
lymphangiogenic factors detected in tumor tissues of 
our group of patients showed no statistically significant 
difference when compared with tumor-adjacent normal 
bladder tissues, except for VEGF-A. In contrast, we found 
significantly higher expression levels of three factors 
(PDPN, LYVE-1, SLP-76) mainly involved in lymphatic 
commitment and development when using normal tissues 
as references and after stratification of patients based on 
clinical parameters and disease progression.
The co-culture of MEC with each of the BCa cell 
lines confirmed the significant gene overexpression of 
two of the three factors (PDPN and SLP-76) observed in 
LVI+/Ln+ MIBC patients with clinical progression. This 
increase seemed to be VEGF dependent, because direct 
stimulation of MEC with VEGF-A and VEGF-C induced 
a similar gene profile as seen when co-culturing MEC with 
BCa cell lines with either secreted amount of VEGF-A or 
VEGF-C.
Data aimed at defining the role of lymphangiogenic 
growth factors in BCa progression showed that the in 
vitro expression of VEGF-A, VEGF-C, and VEGF-D, 
as detected in BCa cell lines, varies among histological 
variants of BCa and correlates with grading. VEGF-C was 
highly expressed in high-grade tumor cells from invasive 
bladder cancers while VEGF-A in low-grade tumor cells 
from a non-invasive papillary carcinoma. Although the 
role of VEGF-A in tumor angiogenesis is established [24], 
our findings confirmed VEGF-A as inducer and maintainer 
of a metastatic status in draining lymph nodes [25, 26] 
and indicate its involvement (with the latter function) in 
the progression of NMIBC into MIBC. In fact, patients 
with metastatic BCa treated with monoclonal antibody 
(i.e., bevacizumab) targeting VEGF-A showed a better 
outcome [27].
The increase in gene transcripts of factors involved 
in lymphatic endothelial cell migration and maturation, 
such as LYVE-1, PDPN, CCL21, Fox-2, and EFNB-2 by 
VEGF-C induction was confirmed in MEC. In addition, 
VEGF-C and to a lesser extent, VEGF-A, but not 
VEGF-D, could directly enhance the migration potential 
of MEC. These findings corroborated VEGF-C as a driver 
of lymphangiogenesis in BCa. In addition, they pointed 
out the support that VEGF-A provides to synergistically 
induce the expression of endothelial factors and receptors 
in MEC. In contrast, our findings could not confirm the 
predictive role of VEGF-D in BCa progression and disease 
outcome, as recently observed either locally by others [10] 
or systemically by us [13]. Rather, the higher expression 
of VEGF-D in LVI-/Ln- NMIBC patients and its slightly 
higher expression in low-grade tumor cells, although both 
lack significance, is controversial. The expression of the 
VEGF-D gene close to the limit of detection (10−7-fold 
change to CD31) observed in tumor-adjacent normal 
tissues from LVI-/Ln- NMIBC patients could have led to 
overestimation of the VEGF-D expression level in this 
group of patients.
Among all factors tested, SLP-76 showed the 
highest significantly increased expression in each 
zco-culture performed. Particularly, VEGF-C elicited 
the highest fold-change at either established (>10-
fold over the baseline) or standard (>300-fold over the 
baseline) concentration. To validate gene expression 
data, SLP-76 protein was detected at either constitutive 
level or after stimulating MEC with VEGF-A and 
VEGF-C. Finally, SLP-76 expression was strongly 
correlated with the ability of MEC cells to migrate upon 
VEGF-C induction.
SLP-76 is a signaling protein whose main role is to 
drive the separation of blood from lymphatic endothelial 
cells [28]. It is regularly produced by platelets while the 
generation of new lymphatic vasculature, mainly sprouting 
from pre-existing blood vessels, is typically enhanced by 
PDPN triggering of platelets. Its expression in lymphatic 
endothelial cells or precursor cells is required for vascular 
separation during development [29]. Therefore, the 
significant expression of SLP-76, together with that of 
LYVE-1 and PDPN, observed in our cohort of patients led 
us to believe that its role in bladder tumor spreading might 
be preeminent and deserves further investigation. Our 
data suggest a robust expression of this signaling protein 
in bladder microvascular endothelial cells under VEGF-A 
and VEGF-C induction. It is thus tempting to speculate 
that VEGF-induced SLP-76 orchestrates the development 
of new lymphatic vasculature from pre-existing lymphatic 
vessels in BCa [29]. However, SLP-76 overexpression 
in MEC is not documented. We are aware that technical 
problems could generate an artifact at the level of gene 
expression. Particularly, by normalizing gene data to low 
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constitutive levels, an overestimation can occur. However, 
in support of our findings, any expression of the SLP-76 
gene in MEC at a constitutive level was always above the 
detection limit (10−7-fold change to CD31). In addition, to 
test the integrity of our investigation, we used as a control 
LEC in which SLP-76 expression is not expected. We 
confirmed the absence of SLP-76 in LEC at both gene and 
protein levels. Moreover, this expression in MEC cannot 
be attributed to their senescence after increased passages, 
because all our experiments were performed on cell lines 
between passage 5 and 9.
In conclusion, the very novelty of this investigation 
was the expression at high concentration of SLP-76 ex 
vivo in progressive LVI+/Ln+ MIBC and in vitro in MEC 
upon VEGF induction. This finding opens the question 
of whether SLP-76 produced within the BCa tumor 
environment could influence cancer lymphangiogenesis 
and predispose the patient to a worse prognosis.
MATERIALS AND METHODS
Patients and tumor classification
Patients diagnosed with aggressive bladder cancer 
who underwent radical cystectomy and bilateral pelvic 
lymph node dissection at the University Hospital of Zurich 
between 2009 and 2013 were consecutively enrolled. For 
this study, only 23 patients could be included because 
enough tumor and non-tumor material was provided after 
routine inspection and diagnostic of the bladder specimen 
by an expert pathologist. To simplify classification of 
urinary bladder cancers, we adopted the EAU guideline 
https://uroweb.org/wp-content/uploads/EAU-Guidelines-
Non-muscle-invasive-Bladder-Cancer-2015-v1.pdf. 
Therefore, all non-invasive papillary carcinomas, 
carcinoma in situ and tumors only invading subepithelial 
connective tissue were grouped as non-muscle invasive 
bladder cancer (NMIBC). Tumors showing evidence of 
invasiveness from superficial muscles to surrounding 
organs were grouped as muscle invasive bladder cancer 
(MIBC). All patients provided written informed consent 
and the study was approved by the Cantonal Ethical 
Committee of Zurich (KEK-StV-Nr. 02/09).
Tissue processing
All pathological specimens were processed 
according to standardized institutional procedures. 
Immediately after complete removal, the bladder was 
examined by an experienced pathologist and both tumor 
and tumor-adjacent tissues were obtained from each 
patient enrolled. Specimens were cut into small pieces and 
snap frozen in liquid nitrogen. Then, tissues were ground 
with a chilled mortar and pestle for quality RNA extraction 
(Ambion RNA Aqueous Kit, Thermo Fisher Scientific, 
Switzerland).
Cell lines
Three human BCa cell lines (HTB-2 or RT4, 
HTB-9 and HTB-4 or T24) with different tumor grading 
[30, 31] were obtained from the American Type Culture 
Collection (ATCC, LGC Standards, USA). The low-
grade RT4 cell line was developed from a non-invasive 
transitional cell papilloma of the bladder. The high-grade 
HTB-9 and T24 cell lines were developed from primary 
high invasive carcinomas of the bladder. The human 
uroepithelial cell line UROtsa was a kind gift from Prof. 
Scott Garrett, Department of Pathology, University of 
North Dakota, USA. BCa cell lines were maintained in 
RPMI medium supplemented with 100 μg kanamycin, 1 
mM GlutaMAX, 1 mM sodium pyruvate, 10 mM HEPES 
and non-essential amino-acids (all from Gibco, Paisley, 
Scotland), as well as 10% heat-inactivated fetal calf serum 
(FCS) (Thermo Fisher Scientific, Switzerland). UROtsa 
cells were maintained in Dulbecco’s Modified Eagles 
Medium (DMEM) composed of a 1:1 mixture of DMEM 
and Ham’s F-12 supplemented with 100 μg kanamycin, 1 
mM GlutaMAX, 1 mM sodium pyruvate, 10 mM HEPES 
and non-essential amino-acids (all from Gibco, Paisley, 
Scotland) and 10% heat-inactivated FCS (Thermo Fisher 
Scientific, Switzerland). The gene expression of Uroplakin 
II (UPII; marker of terminally differentiated urothelium and 
sensitive marker for urothelial carcinomas [32, 33]) and 
Maspin (a serine-protease that inhibits tumor growth and 
metastasis [34]) were tested to confirm the cancer grading 
and potential invasiveness of the three cancer cell lines 
used in this study. UPII gene expression was detected in all 
three cell lines at levels relative to the tumor grade (1000-
fold greater in RT4 than in T24). Maspin gene expression 
was 5-fold higher in RT4 than in T24 and HTB-9 (data 
not shown). The human primary bladder microvascular 
endothelial cells (HBdMEC; hereafter MEC) were obtained 
from Lonza (Basel, Switzerland) while the human dermal 
lymphatic endothelial cells (juvenile foreskin; HDLEC; 
hereafter LEC) were obtained from PromoCell (Heidelberg, 
Germany). Both endothelial cell lines were cultured as 
follows: flasks or wells were coated with collagen (50 μg/
ml in PBS; BD Bioscience, Switzerland) for at least 20 min 
at room temperature. Cells were then seeded in EBM-2 
basal medium (Lonza, Basel, Switzerland) supplemented 
with 100 μg kanamycin, 1 mM GlutaMAX, and 20% heat-
inactivated FCS (Thermo Fisher Scientific, Switzerland), 
25 μg/ml of cAMP and 10 μg/ml of Hydrocortisone 
(Sigma-Aldrich, Switzerland). All experiments were 
performed with endothelial cells at passage 9 or lower. 
For MEC/LEC stimulation, either VEGF-A protein 
(H00007422-Q01, Abnova, Walnut, CA, USA) or VEGF-C 
protein (H00007424-P01, Abnova, Walnut, CA, USA) were 
used. All cell lines were cultured in saturated humidity at 
37 °C, under 5% CO2, and 95% air. The number of cells to 
be plated was adjusted according to cell size. Three-day 
culturing was the appropriate time span for all cell lines to 
reach 90%–100% confluence (harvesting time).
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Trans-well assay
For co-culturing, MEC were first grown in a 24-
well plate to reach 80% confluence. Then, cells were co-
cultured with either bladder cancer cells lines (MEC/RT4, 
MEC/HTB-9 or MEC/T24) or the control cell line (MEC/
UROtsa), already grown in inserts to avoid direct contact 
with MEC, for 24 h.
Gene expression analysis
After cell harvesting, total RNA was extracted from 
each cell line condition according to the manufacturer’s 
instructions (RNA Aqueous Kit, Thermo Fisher Scientific, 
Switzerland) and transcribed into cDNA (High Capacity 
cDNA Reverse Transcriptase Kit, Applied Biosystems 
Rotkreuz, Switzerland) to perform gene expression by 
qRT-PCR. Assays were performed with the TaqMan Gene 
Expression Assay Kit (Applied Biosystems, Rotkreuz, 
Switzerland) using “on demand” sets of primers and 
probes for lymphangiogenic factors and endothelial cell 
receptors. Reactions were run using the Rotor-Gene 3000 
(Corbett Life Science, Sydney, Australia) in a final volume 
of 20 μl/reaction (19 μl TaqMan mix and 1 μl cDNA). 
To quantify copy numbers of genes, standard curves from 
each condition of all cell lines were generated using 1:10 
cDNA serial dilutions for each gene tested at known 
concentration (108 to 103). Beta actin and PECAM1 
(CD31) were used as housekeeping genes [21]. Ribosomal 
RNA subunit 18 (rRNA18S) was used to test the integrity 
of our assay. Normalized data were evaluated as relative 
quantification by using the 2–ΔΔCt method to compute fold 
changes among experimental conditions. When indicated, 
absolute copy numbers of genes were calculated.
Protein analysis and expression
The production of VEGF-A, VEGF-C and 
VEGF-D proteins in supernatants of bladder cell lines 
was analyzed by using either the human VEGF-A 
enzyme-linked immunosorbent assay (ELISA) Kit 
(BMS277) or the human VEGF-C ELISA Kit (BMS297; 
Bender MedSystems, Wien, Austria) according to the 
manufacturer’s instructions. The detection of VEGF-D 
was analyzed by human VEGF-D ELISA Kit (LS-
F27835; LSBio. Seattle, WA, USA). The supernatant was 
loaded into a 96-well plate, including standard controls. 
Protein concentrations were measured with an Emax Plus 
Microplate Reader and analyzed by SoftMax Pro Software 
(Molecular devices, Sunnyvale, CA, USA).
Scratch wound healing assay
Endothelial cells were seeded in triplicate in 24-
well plates and grown until confluent. Cells were then 
incubated overnight in serum-reduced medium containing 
1% FBS. Identical scratches (two crosses were scratched 
in each well) were generated with a 200-μl sterile pipette 
tip. Any cellular debris was removed by washing with 
PBS. Serum-reduced medium was replaced and cells 
were instantly centre-imaged at 5× magnification, using a 
Zeiss Axiovert 200 M microscope equipped with a Zeiss 
AxioCam MRm camera with maximum contrast (Carl 
Zeiss AG, Feldbach, Switzerland, software: Axio Vision 
Rel. 4.7). For cell stimulation, either VEGF-A or VEGF-C 
protein were added to the wells at a final concentration 
of 50 ng/ml. After 24 h, the medium was replaced with 
PBS and the closure of the scratch by migrating cells was 
analyzed. Data were evaluated using the Tscratch Software 
with default parameter settings.
Flow cytometry
Stimulated or non-stimulated endothelial cells 
were stained extracellularly with anti-CD31-fluorescin 
isothiocyanate (FITC) and intracellularly (either before 
or after stimulation) with anti-SLP-76 allophycocyanin 
(APC) antibodies (BD Biosciences, Allschwil, 
Switzerland). As control, stimulated (anti-CD3) or non-
stimulated enriched human CD8+ T cells (MACS cell 
separation, Miltenyi Bergisch Gladbach, Germany) 
were stained extracellularly with anti-CD8-FITC 
and intracellularly with anti-SLP-76 APC antibodies 
(BD Biosciences, Allschwil, Switzerland). Data were 
acquired on a LSR II Fortessa flow cytometer equipped 
with FacsDIVA software (BD Biosciences, Allschwil, 
Switzerland).
Western blot
Endothelial cells were stimulated with either VEGF-A 
or VEGF-C at a final concentration of 50 ng/ml for 3, 6, and 
12 h. Lysates of VEGF-treated and non-treated cells were 
prepared by a 1 h incubation on ice with 100 μl of M-PER 
Mammalian Protein Extraction Reagent and a cocktail 
of protease inhibitors (Halt Protease Inhibitor Cocktail, 
Thermo Scientific, Waltham, MA, USA), and subsequent 
disruption by sonication. After centrifugation for 20 min, 
protein concentrations were determined in supernatants 
by a standard Bradford assay. Equal amounts of protein 
(30 μg) were loaded and separated on an SDS-PAGE gel. 
After transfer to nitrocellulose membranes, proteins were 
incubated with the primary antibody SLP-76 (Santa Cruz 
Biotechnology, Dallas, Texas, USA) overnight at 4 °C and 
subsequently with a secondary antibody for 1 h, developed 
with Armersham ECL Western Blotting Detection Reagent 
(GE Healthcare, Waukesha, WI, USA) and finally, exposed 
to film. Beta-actin (Abcam, Cambridge, UK) was used as 
the control gene.
Immunofluorescence
Endothelial cells were cultured in Lab-tek chambers 
and allowed to grow until they reached approximately 
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80% confluence. Stimulations with either VEGF-A or 
VEGF-C were performed at standard concentrations 
and times as described above. Cells were fixed with 
4% paraformaldehyde for 10 min at room temperature, 
permeabilized with 1 ml 0.5% Triton X-100 and blocked 
with 1% BSA. Cells were then incubated for 1 h with the 
primary antibody SLP-76 (Santa Cruz Biotechnology 
Dallas, Texas, USA) and overnight at 4°C with the 
Cy3-conjugated secondary antibody. Dapi was used for 
staining of nuclei and FITC-conjugated phalloidin for the 
cytoskeleton. Immunofluorescence images were digitally 
recorded with a Leica CTR6000 microscope (Leica, 
Heerbrugg, Switzerland).
Statistical analysis
Statistical analysis was performed with GraphPad 
Prism (v5.1) and SAS/STAT (v9.1). The data were 
reported as mean ± standard error (SE) with median 
values and ranges where appropriate. Distributions of 
categorical markers were analyzed by Fisher’s exact test. 
When comparing numerical markers, non-parametric 
tests, such as the Mann-Whitney U test, Wilcoxon signed 
rank test and Kruskal-Wallis test were used. The Pearson 
correlation coefficient was used to measure the strength 
of linear associations. Differences were considered 
significant at p < 0.05 (CI 95%).
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